In vitro Characterization of Nanomedicines

Scientific Leaders of the project: Javier García, José Luis Pedraz, Simó Schwartz & Ramón Mangues.
Coordinator of the project: Ibane Abasolo & Javier García

Industrial problem/gap covered

One of the causes that increase the time to market of nanotherapeuticsis its preclinical validation. The standard protocols for more traditional drugs are not applicable for nanomedicines. NANBIOSISoffers a preclinical study plan tailored to meet the demands of each nanomedicine product, developed in collaboration with the user and starting from a set of basic analytical tests to more sophisticated experiments.

Description

We offer a complete In vitro Characterization. e.g., immunology, cytotoxicity, hematology, oxidative stress, etc, and more adapted to the different products by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter.

Sodiumcolistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. M. Pastor. M. Moreno-Sastre, A. Esquisabel, E. Sans, M. Viñas, D.lBachiller, V. J. Asensio, Á. Del Pozo, E. Gainza, J. L. Pedraz. Int. J. of Pharm. 477 (2014) 485-494.

Intrapericardial Delivery of Cardiosphere-Derived Cells: An Immunological Study in a Clinically Relevant Large Animal Model. Blázquez R, Sánchez-Margallo FM, Crisóstomo V, Báez C, Maestre J, Álvarez V, Casado JG. PLoS One. 2016 Feb 11;11(2):e0149001. doi: 10.1371/journal.pone.0149001. eCollection 2016.

Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on in vitro Stimulated T Cells. Blazquez R, Sanchez-Margallo FM, de la Rosa O, Dalemans W, Alvarez V, Tarazona R, Casado JG. Front Immunol. 2014 Nov 4;5:556. doi: 10.3389/fimmu.2014.00556. eCollection 2014.

Services involved: